TGN1412, a superagonistic CD28-specific antibody, was shown to require Fc-crosslinking or immobilization as a prerequisite to mediate T cell proliferation and cytokine release in vitro.
Introduction
Monoclonal antibodies (mAbs) are widely used for therapeutic applications. Although, therapeutic mAbs are potent and effective agents, they can induce severe adverse events including cytokine release syndrome (CRS), a cascade of systemic cytokine release.
The first mAb approved 1986 as a drug for humans, muromonab (Orthoclone OKT3), is a murine anti-human CD3 mAb, indicated for the treatment of acute renal, steroid-resistant cardiac, or steroid-resistant hepatic allograft rejection. In particular during the first infusion, OKT3-mediated T cell activation can induce massive cytokine release, possibly culminating in a CRS 1;2 . Currently, about 29 mAbs are available on the market in the EU, including those directly influencing T cell function.
For proper T cell activation, at least two signals are required: The first signal is provided by the T cell receptor (TCR) upon recognition of antigen:MHC-complexes on the surface of antigen presenting cells (APCs). However, antigen alone is not sufficient to drive activation of naïve T cells. To fully activate resting naïve T lymphocytes, a second signal which emerges from triggering of so called co-stimulatory molecules must be provided (reviewed in 3 ). The transmembrane CD28 homodimer is the most prominent co-stimulatory molecule. Its ligands B7-1 (CD80) and B7-2 (CD86) are upregulated on APCs upon triggering of cells with danger signals derived from pathogens such as bacteria or viruses or upon cytokine stimulation 4 . As for signal one, triggering of CD28 alone is not capable of inducing T cell activation, whereas simultaneous engagement of the TCR and CD28 leads to activation of resting T lymphocytes.
Another important co-stimulatory molecule is ICOS (inducible co-stimulator; CD278) binding to its ligand LICOS (CD275), expressed on APCs, B cells, and endothelial cells 5;6 .
Homodimeric ICOS, a member of the CD28 immunoglobulin super family, is upregulated following T cell activation, initiating a cascade of events that can shape key aspects of immune responses including T cell differentiation, proliferation, and secretion of Th1, Th2, and Th17 associated cytokines such as TNF-α and IFN-γ, IL-4, IL-5, IL-10, and IL-17 7;8 .
TGN1412 belongs to a class of superagonistic anti-CD28 antibodies, able to activate T cells without any additional TCR/CD3 triggering. During the last two decades, those antibodies have been used to analyze CD28-mediated signaling pathways and to assess how CD28
facilitates activation and differentiation of murine, rat, and human T lymphocytes. In 2006,
For personal use only. on October 31, 2017 . by guest www.bloodjournal.org From TGN1412, intended for the treatment of rheumatoid arthritis and B cell chronic lymphocytic leukemia, was applied to healthy volunteers during a phase I clinical trial, inducing unexpected serious adverse events. These were associated with the induction of a CRS, i.e. the release of high amounts of pro-inflammatory cytokines, most notably TNF-α and IFN-γ 9 .
We and others showed that T cell proliferation and cytokine release upon TGN1412 in vitro stimulation of either T cells, whole blood or PBMCs fails upon stimulation with soluble TGN1412. Immobilized or IgG crosslinked TGN1412 indeed was able to induce cell activation indicating contribution of the antibody's Fc-part to its function [10] [11] [12] [13] . So far, it is not clear which cell and which Fc receptor (FcR) mediates TGN1412 crosslinking and to which extent FcR expressing cells contribute to cytokine release or T cell stimulation.
Interestingly, Fc ligation by FcγRs was reported to contribute to OKT3-mediated CRS. Here, the interaction of T cell-bound antibody with FcRs on monocytes and other cells critically contributed to antibody-mediated CRS [14] [15] [16] . In studies with chimpanzees using OKT3 variants unable to bind FcRs, induction of less severe side effects was observed when compared to OKT3 17;18 . Likewise, OKT3 variants which show a 100-fold reduced binding to FcγRI (CD64) and FcγRII (CD32) were much less effective in inducing human T cell proliferation and cytokine release (e.g. TNF-α and IFN-γ) 19 .
In the present study, we show that primary human umbilical vein endothelial cells (HUVECs)
are able to confer TGN1412-mediated T cell activation. Unexpectedly, Fc-FcR interaction is completely dispensable whereas ICOS-LICOS interaction between TGN1412-treated T cells and HUVECs is both necessary and sufficient to mediate TGN1412-induced T cell proliferation. Of note, cytokine stimulation enhances LICOS expression on HUVECs and
ICOS-LICOS interaction upregulates ICOS expression on TGN1412-treated T cells suggesting a model of positive feedback conferred by ICOS-LICOS interaction.
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Materials and Methods

T cell and B cell purification
Peripheral blood mononuclear cells (PBMCs) were isolated from buffy coats from healthy donors (Blutspendedienst Frankfurt am Main, Germany) by Ficoll (Biochrom, Berlin, Germany) density gradient centrifugation. Human T cells or B cells were further purified by non-T cell or non-B cell depletion using the Pan T cell isolation kit II or B cell isolation kit II (Miltenyi Biotec, Bergisch Gladbach, Germany). Purity of T cells usually exceeded 97%. All cells were cultured at 37°C with 5% CO 2 in 96-well (2x10 5 cells in 200 µl medium) or 24-well (1x10 6 cells in 1 ml medium) flat-bottom tissue culture plates (Sarstedt, Nümbrecht, Germany) using X-VIVO 15 medium (Lonza, Basel, Switzerland).
Isolation and stimulation of human umbilical vein endothelial cells (HUVECs)
HUVECs were isolated from human umbilical cords obtained from healthy donors Growth Medium (PromoCell, Heidelberg, Germany). Cytokines were added to the medium with final concentrations of 200 U/ml TNF-α and 100 U/ml IFN-γ (both from Peprotech, Hamburg, Germany) for three days.
Stimulating antibodies
Usage of the humanized superagonistic anti-CD28 antibody TGN1412 was kindly permitted by TheraMAB GmbH (Würzburg, Germany). Murine anti-CD3 antibody Orthoclone OKT3
was purchased from Janssen Cilag (Neuss, Germany). 
Flow cytometric analysis
For flow cytometric analysis, T cells or HUVECs were stained for 20 min at 4°C using the following monoclonal antibodies diluted to the optimal concentration: anti-CD3-APC (clone 
Transwell Assays
For transwell assays, transwell permeable supports (Corning, NY, USA) with 0.4 µm pore size polycarbonate membrane or polyester membrane were used. After an initial equilibrium period of the transwell permeable supports, irradiated HUVECs were cultured for three days in 24-well or 12 mm diameter transwell insert. On day three, HUVECs were washed with PBS (Biochrom, Berlin, Germany) and T cells were added to transwell insert or 24-well, respectively.
Analysis of cytokine secretion
After stimulation as described, cell-free supernatant was collected and analyzed by FlowCytomix Th1/Th2 11plex kit (Bender MedSystems, Vienna, Austria) according to the manufacturer's recommendations. 
Preparation of deglycosylated TGN1412
In order to yield deglycosylated TGN1412 with an otherwise intact core protein structure, the sample was enzymatically deglycosylated under non-denaturing conditions. Residual glycosylated forms were eliminated by affinity chromatography using immobilized wheat germ lectin (WGA-Agarose; Calbiochem, Darmstadt, Germany). 100 µl TGN1412, corresponding to 1 mg protein, were incubated with 20 µl N-glycosidase F (Roche, Pensberg, Germany, 1000 U/ml) for 16 h at 37°C. 100 µl thereof was mixed with PBS (150 mM NaCl; 10 mM sodium phosphate pH 7.5) and loaded onto a WGA-Agarose column equilibrated to the same buffer. Unbound protein was eluted with PBS and the protein containing fraction was collected.
A negative control was prepared by incubating TGN1412 without N-glycosidase F followed by mock affinity chromatography on a non lectin containing agarose which was blocked with ethanolamine (included in WGA-Agarose kit from Calbiochem, Darmstadt, Germany). This control preparation is termed TGN1412* in the following.
Protein concentration of both glycosylated and deglycosylated antibody preparations was determined using HPLC size-exclusion chromatography. The success of deglycosylation was verified by capillary SDS electrophoresis using the Beckman IgG heterogeneity test kit.
Results
Endothelial cells confer TGN1412-mediated T cell activation
T cell proliferation can be mediated by crosslinking TGN1412 via a secondary anti-IgG antibody or by immobilization via coating the antibody onto tissue culture plates ( Figure 1A ).
Here, crosslinking of TGN1412 via an anti-IgG antibody was performed in aqueous solution.
This experimental setup was shown to confer TGN1412-mediated T cell activation in previous studies 12 . TGN1412 was added at 0.1 µg/ml, 1 µg/ml or 10 µg/ml. In all experimental settings tested, 1 µg/ml induced the strongest T cell proliferation (data not shown). Therefore, all following experiments were performed at 1 µg/ml. This also resembles the concentration of TGN1412 that theoretically was present in the blood of volunteers treated during the phase I clinical trial of the antibody 13 .
Upon intravenous application of any antibody, peripheral blood cells and endothelial cells are the first cell types getting into contact with the antibody. In our study, we used primary human umbilical vein endothelial cells (HUVECs) and analyzed their ability to induce activation of TGN1412-treated T cells. We confirmed that primary human T cells did not show proliferation upon stimulation with soluble TGN1412 alone ( Figure 1A ). Nevertheless,
co-cultivation of TGN1412-treated T cells with HUVECs induced T cell proliferation that
was augmented using cytokine pre-stimulated HUVECs ( Figure 1B ). For pre-stimulation TNF-α and IFN-γ were used, two cytokines markedly induced upon TGN1412 treatment in vivo 9 . In absence of TGN1412, HUVECs alone, either untreated or cytokine pre-stimulated,
were not able to confer T cell proliferation ( Figure 1B ) making any allo-reaction related effects or effects of potential residual cytokines unlikely. Thus, primary human endothelial cells confer TGN1412-mediated T cell proliferation.
T cell proliferation was measured on day 1, day 3, and on day 5 of stimulation. Upon all experimental settings tested, the strongest proliferative responses were observed between day 3 and day 5. Stimulation for additional two days did not increase T cell proliferation (data not shown).
Already after 24 hours short-term co-cultivation of TGN1412-treated T cells and TNF-α plus IFN-γ pre-stimulated endothelial cells, TGN1412-mediated cytokine release was detectable ( Figure 2A ). Cytokine patterns induced upon crosslinking TGN1412 using an anti-IgG antibody differed from that obtained when primary human endothelial cells were used to mediate activation of TGN1412-treated T cells (Figure 2A ). In particular, we found higher levels of IFN-γ, IL-6, and IL-8 in co-cultures at that early time point. At day 5 of stimulation, crosslinking TGN1412 via an anti-IgG antibody induced an enhanced and broader cytokine pattern, while some cytokines present in the co-culture system were no longer detectable (suppl. Figure 1) . Adding an anti-IL-2 blocking antibody diminished endothelial cellmediated proliferation of TGN1412-treated T cells by more than 80% (suppl. Figure 2) indicating the contribution of this induced cytokine to T cell proliferation.
In line with early cytokine secretion, early T cell activation markers CD69 and CD25 were upregulated on a proportion of TGN1412-treated T cells already 24 hours after co-cultivation with endothelial cells and mitogenic activity of TGN1412 was detectable already upon 48 hours co-cultivation ( Figure 2B ). In order to test whether ICOS-LICOS interaction was not only necessary but sufficient to confer TGN1412-mediated T cell proliferation, we used recombinant LICOS protein (rLICOS) to stimulate TGN1412-treated T cells. When rLICOS was coated onto cell culture plates, TGN1412-treated T cells were able to proliferate without the addition of any crosslinking reagent or any additional cell type ( Figure 5A ). This rLICOS-mediated proliferation of TGN1412-treated T cells was completely abolished by adding anti-LICOS blocking antibodies (data not shown). Interestingly, when rLICOS was added soluble into culture medium of TGN1412-treated T cells, no T cell proliferation was observed ( Figure   5A ). In line with anti-CD40 blocking experiments, which did not inhibit HUVECs-mediated proliferation of TGN1412-treated T cells (compare Figure 4C) , recombinant CD40 protein (rCD40) did not induce proliferation of TGN1412-treated T cells ( Figure 5A ). Thus, ICOS-LICOS interaction is both necessary and sufficient to mediate TGN1412-induced T cell proliferation in our experimental setting.
Fc-FcR interaction is dispensable for endothelial cell-conferred TGN1412-mediated T cell proliferation
ICOS-LICOS interaction induces ICOS upregulation on TGN1412-treated T cells
We showed that cytokine stimulation upregulated LICOS expression on human endothelial cells and that blocking LICOS on these cells significantly reduced proliferation of TGN1412-treated T cells in co-culture (see Figure 4B and C, respectively). Next, we addressed the question whether this cell to cell interaction also affected expression of LICOS interaction partner ICOS on TGN1412-treated T cells. In contrast to stimulation of T cells with TGN1412 alone, ICOS expression on T cells was strongly upregulated upon TGN1412 crosslinking using an anti-IgG antibody and upon addition of T cells to wells coated with TGN1412. Importantly, also co-cultivation of cytokine pre-stimulated HUVECs with Figure 5B ). Moreover, experiments using rLICOS coated onto cell culture plates revealed that ICOS-LICOS interaction was sufficient to upregulate ICOS on TGN1412-treated T cells ( Figure 5B ). This
TGN1412-treated T cells upregulated ICOS expression on T cells (
rLICOS-mediated upregulation of ICOS on TGN1412-treated T cells was completely abolished by adding anti-LICOS blocking antibodies (data not shown). As a control, rCD40
was coated which did not induce proliferation of TGN1412-treated T cells ( Figure 5A ). Endothelial cells play an important role in the recruitment of T cells and their activation at sites of inflammation [28] [29] [30] . We and others showed that human endothelial cells constitutively We found that interaction of LICOS, expressed on HUVECs, with ICOS on T cells is both necessary and sufficient to mediate TGN1412-induced T cell proliferation ( Figure 4C and 5A). Cytokine stimulation enhanced LICOS expression on HUVECs and furthermore, ICOS-LICOS interaction upregulated ICOS expression on TGN1412-treated T cells ( Figure 4B and 5B). For cytokine stimulation of HUVECs, we used TNF-α and IFN-γ, which are also secreted in our endothelial cell/T cell co-cultivation assay after short-term incubation ( Figure   2A ). Hence, we provide a model of positive feedback conferred by ICOS-LICOS interaction between TGN1412-treated T cells and endothelial cells. In our experimental model, TNF-α and IFN-γ were added exogenously. Whether cytokine pre-stimulation of endothelial cells is needed to initiate this positive feedback loop or needed in order to enhance it will be a matter of future investigations.
However, blocking ICOS-LICOS interaction did not completely abolish TGN1412-induced T cell proliferation mediated by HUVECs suggesting that additional molecular interactions
For personal use only. on October 31, 2017. by guest www.bloodjournal.org From between both cell types could be involved in TGN1412-mediated T cell activation. On the other hand, it cannot be ruled out that the anti-LICOS antibody is not blocking with a 100% effectiveness, as is has been reported for other blocking antibodies 35 . This latter suggestion is supported by our experiments using an anti-ICOS blocking antibody which reduced rLICOSmediated proliferation of TGN1412-treated T cells by more than 90% ( Figure 5C ).
In the present study, we used . In line with this, we found that T cells proliferating upon TGN1412/LICOS stimulation showed higher ICOS expression than those showing less responsiveness to the same treatment (data not shown).
Yao et al. just recently showed that in addition to ICOS-LICOS interaction, human LICOS is a co-stimulatory ligand for CD28 facilitating anti-CD3-mediated T cell activation 35 . Of note, in our experimental setting using coated recombinant LICOS protein, the interaction between 
